

**31st Annual Scandinavian Atherosclerosis Conference**  
April 2-5, 2025 at Krogerup Højskole, Humlebæk, Denmark



# 2025 Program

Sponsored by:





**SCIENTIFIC COMMITTEE**

Clare Hawkins (Denmark)  
Bente Halvorsen (Norway)  
Ida Juul Rasmussen (Denmark)  
Jacob Juel Christensen (Norway)  
Paolo Parini (Sweden)  
Patrick Rensen (Netherlands)  
Eva Hurt-Camejo (Sweden)  
Mia Ståhle (Finland)

**OFFICE**

Kirsten B Holven  
Department of Nutrition  
University of Oslo  
Norway  
Email: [kirsten.holven@ssar.dk](mailto:kirsten.holven@ssar.dk)

***Organized by*****SCANDINAVIAN SOCIETY  
FOR ATHEROSCLEROSIS  
RESEARCH**

Kirsten B Holven (Chairman)  
Frida Emanuelsson (Treasurer)  
Liv Tybjærg Nordestgaard (Social Media)  
Jacob J. Christensen (Social Media)  
Matteo Pedrelli (Webmaster)  
Minna Kaikkonen-Määttä  
Pirkka-Pekka Laurila  
Vilmundur Gudnason  
Gunnar Sigurdsson  
Stefano Romeo  
Monique Mulder  
Patrick Rensen

**WWW**

[www.ssar.dk](http://www.ssar.dk) (Matteo Pedrelli, Webmaster)

## Wednesday, April 2nd, 2025

16.00 – 18.00	Arrival, registration, and coffee (dining room until 17.45)
18.00 – 19.30	Dinner
19.30 – 19.35	Welcome <b>Kirsten B Holven</b> ( <i>Norway</i> )
<b>THE NIKKILÄ MEMORIAL LECTURE</b>	
19.35 – 19.40	Introduction of the 2024 Nikkilä Lecturer Minna Kaikkonen-Määttä ( <i>Finland</i> )
19.40 – 20.25	<u>2025 Nikkilä Lecture</u> The promiscuous apolipoprotein M: good, bad and something in between <b>Christina Christoffersen</b>
20.25 – 20.45	Discussion
20.45 –	Pub will be open

Thursday, April 3rd, 2025

07.30 – 08.30	Breakfast
<b>SESSION I</b>	<b>INFLAMMATION AND VASCULAR BIOLOGY</b> Chaired by <b>Bente Halvorsen</b> (Norway) and <b>Clare Hawkins</b> (Denmark)
08.30 – 09.00	<i>Invited speaker</i> Sex influences atherosclerosis in TET2-related clonal hematopoiesis of indeterminate potential and on interleukin-1beta inhibition <b>Amélie Vromman</b> (USA)
09.00 – 09.15	T-cells enhance development of atherosclerosis in LDL receptor knock-out mice <b>Ida Gregersen</b> (Norway)
09.15 – 09.30	N-Terminal proteomics reveals distinct protein degradation patterns in different types of human carotid artery atherosclerotic plaques <b>Michael Davies</b> (Denmark)
09.30 – 09.45	The alpha 7 nicotinic acetylcholine receptor agonist PHA 568487 dampens inflammation in PBMCs from patients with newly discovered coronary artery disease <b>Rebecka Wilhelmsson</b> (Sweden)- YIA
09.45 – 10.00	Proteomics analysis of extracellular vesicle proteins in plasma from patients with atherosclerosis. <b>Yibo Gao</b> - (Denmark)- YIA.
10.00 – 10.45	<b>Poster Walk (Session I)</b> Coffee and tea
10.45 – 11.15	<i>Invited speaker</i> <b>Trisha Grevenkoed</b> (Denmark) Fatty acid-derived mediators in systemic inflammation
11.15 – 11.30	Comparative analysis of smooth muscle cell diversity in atherosclerosis across species and vascular beds <b>Diana Sharysh</b> (Denmark) - YIA
11.30 – 11.45	Sex differences in immunomodulating treatment in cardiovascular diseases <b>Tuva Dahl</b> (Norway)
11.45 – 12.00	Serum Tryptophan and Kynurenine levels and risk of heart failure among patients with chronic kidney disease. <b>Sara Mohiti</b> (Denmark)- YIA
12.00 – 13.00	Lunch

## SESSION II

### CARDIOVASCULAR DISEASE

Chaired by **Ida Juul Rasmussen+** (Denmark) and **Jacob Juel Christensen** (Norway)

13.00 – 13.30

*Invited speaker*

Dispelling the Myths of dietary fats and cardiovascular risk

**Julie Lovegrove** (UK)

13.30 – 13.45

Lipoprotein(a) and risk of dementia: three independent cohort studies including 575,630 individuals

**Peter E. Thomas** (Denmark) - YIA

13.45 – 14.00

Risk reduction of ASCVD attributed to lowering of remnant cholesterol from statins, fibrates, APOC3 inhibitors, and ANGPTL3 inhibitors: a cohort study

**Mie Balling** (Denmark)

14.00 – 14.15

Adherence to lipid lowering therapy in genetic familial hypercholesterolemia and cardiovascular disease risk: a registry cohort study

**Tone Svilaas** (Norway)

14.15 – 14.30

Common genetic variants in GIP and GIPR as proxies for body weight reduction via GIP receptor targeting and risk of cardiovascular disease – observational and Mendelian randomization studies

**Frida Emanuelsson** (Denmark)

14.30 – 15.30

**General meeting of the Scandinavian Society for Atherosclerosis Research**  
Open for all participants

Afternoon free for the Louisiana Museum of Modern Art (5 min walk), beach (5 min walk), Kronborg, the castle of Hamlet (12 min by train) or downtown Copenhagen (50 min by train)

16.00 – 17.00

**The traditional soccer match between countries**

Remember to bring sports clothing and suitable footwear

18.00 – 19.00

Dinner

## SESSION II

### CARDIOVASCULAR DISEASE – continued

Chaired by **Ida Juul Rasmussen** (Denmark) and **Jacob Juel Christensen** (Norway)

19.00 – 19.30

*Invited speaker*

Somatic mutations and cellular clones in atherosclerotic plaques

**Lars Melholt Rasmussen** (Denmark)

19.30 – 20.30

**Poster Walk (Session II)**

Coffee and tea

20.30 – 20.45

Abdominal Aortic Aneurysm Prevalence and Infrarenal Aortic Diameter are decreasing in the Population-based Regional Screening Program

**Antti Siika** (Sweden)

20.45 – 21.00	Cholesterol associates with risk of STEMI above NSTEMI <b>Malene Kærslund Hansen</b> ( <i>Denmark</i> )
21.00 – 21.15	Elevated remnant cholesterol confers high risk of ASCVD without prompting lipid-lowering therapy: an unmet medical need <b>Karen Hvid</b> ( <i>Denmark</i> ) - <i>YIA</i>
21.15 – 21.30	Cardiovascular disease and compliance with lipid-lowering therapy among young individuals with Familial Hypercholesterolemia in Norway – A register study. <b>Gisle Langslet</b> ( <i>Norway</i> )
21.30 –	Pub will be open

## Friday, April 4th, 2025

07.30 – 08.30	Breakfast
<b>SESSION III</b>	<b>LIPOPROTEINS AND LIPID TRANSPORT</b> Chaired by <b>Paolo Parini</b> (Sweden) and <b>Patrick Rensen</b> (Netherlands)
08.30 – 09.00	<i>Invited speaker</i> The genetic background behind the clinical familial hypercholesterolemia phenotype <b>Mafalda Bourbon</b> (Portugal)
09.00 – 09.15	High cholesterol absorption efficiency enhances proatherogenic properties of LDL particles <b>Katariina Öörni</b> (Finland)
09.15 – 09.30	Cholesterol-lowering drug targets reduce risk of vascular-related dementia: Mendelian randomization of 500.000 individuals. <b>Liv Nordestgaard</b> (Denmark)
09.30 – 09.45	Low-Density Lipoprotein Cholesterol, Coronary Plaque burden, and Cardiovascular Risk in individuals beyond 75 years of age: The Western Denmark Heart Registry <b>Malene Højgaard Andersen</b> (Denmark) - YIA
09.45 – 10.00	Hepatic knockdown of ABCA6 increases atherosclerosis in APOE*3-Leiden.CETP mice <b>Patrick Rensen</b> (Netherlands)
10.00 – 11.00	<b>Poster Walk (Session III)</b> Coffee and tea
11.00 – 11.30	<i>Invited speaker</i> Role of HDL in sepsis rather than atherosclerosis <b>Liam Brunham</b> (Canada)
11.30 – 11.45	The Effects of Modulating HDL concentration on Sepsis Risk: A Mendelian Randomization study <b>Mohan Li</b> (Netherlands) - YIA
11.45 – 12.00	Angiopoietin-like 3 (ANGPTL3) deficiency alters hepatic metabolism and promotes substrate rerouting <b>Ottavia Terenghi</b> (Italy)
12.00 – 12.15	Association of HDL cholesterol, apolipoprotein E and A1 concentrations with fetal growth, maturation, and placental insufficiency. <b>Rikke Mohr Lytsen</b> (Denmark) - YIA
12.15 – 13.15	Lunch
<b>SESSION IV</b>	<b>OTHER TOPICS</b> Chaired by <b>Frida Emanuelsson</b> (Denmark) and <b>Mia Ståhle</b> (Finland)
13.15 – 13.45	<i>Invited speaker</i> Sex differences in atherosclerotic disease: Pre- and Post-Menopause <b>Jeanine Roeters van Lennep</b> (Netherlands)



13.45 – 14.00	Statin-associated regulation of hepatic PNPLA3 in patients without known liver disease <b>Osman Ahmed (Sweden)</b>
14.00 – 14.15	Loss-of-function in endothelial lipase increases LDL cholesterol but decreases risk of atherosclerotic cardiovascular disease <b>Benjamin Nilsson Wadström (Denmark)</b>
14.15 – 14.30	Management of hypercholesterolemia in a patient with vanishing bile duct syndrome <b>Lorenzo Luciani (Sweden) - YIA</b>
14.30 – 14.45	Causal insights of LDL cholesterol and triglycerides-rich lipoproteins for risk of dementia <b>Jiao Luo (Denmark)</b>
14.45 – 15.45	<b>Poster Walk (Session IV)</b> Coffee and tea
15.45 – 16.15	<u>Invited speaker</u> Novel imaging approaches to diagnose CAD and their ability to monitor treatment response <b>Sarah Bär (Switzerland)</b>
16.15 – 16.30	Combined use of cardioprotective glucose-lowering drugs and statins for primary prevention of atherosclerotic cardiovascular disease in individuals with type 2 diabetes: A nationwide cohort study <b>Tummas Ternhamar (Denmark)- YIA</b>
16.30 – 16.45	Current guidelines result in extensive pregnancy-related off-treatment time in women with familial hypercholesterolemia <b>Marianne Klevmoen (Norway) - YIA</b>
16.45 – 17.00	Role of HDL in reproduction - the cholesterol efflux capacity of follicular fluid HDL predicts normal fertilization independent of HDL cholesterol levels. <b>Uwe Tietge (Sweden)</b>
17.00 – 17.15	Remnant cholesterol lowering in cardiovascular disease risk reduction in statin trials: meta-regression analyses <b>Børge Grønne Nordestgaard (Denmark)</b>
17.15 - 17.20	Concluding remarks <b>Kirsten B. Holven (Norway)</b>
18.30 – 19.00	<b>Cocktail</b>
19.00 –	<b>Banquet and dancing</b>

**Saturday, April 5th, 2025**

08.30 – 10.00

Breakfast and departure

**Safe travels and see you next year**

**31st Annual Scandinavian Atherosclerosis Conference**  
April 2-5, 2025 at Krogerup Højskole, Humlebæk, Denmark



**2025 Posters**

**Thursday, April 3, 2025**

Posters are displayed in “Lille Sal”. Posters should be in place before 9.00 and removed after the last poster session of the day. You should be present at your poster during all poster sessions of the day. Your poster should be placed on the board with your number on.

**SESSION I**

**INFLAMMATION AND VASCULAR BIOLOGY**

- No. 01** Role of immune cells in the developmental programming of atherosclerosis  
**Clare Hawkins** (Denmark)
- No. 02** Anti-inflammatory effects of a GLP-1 receptor agonist in comparison with an anti-IL-6 antibody in a mouse model of accelerated atherosclerosis  
**Louise Marie Voetmann** (Denmark)
- No. 03** Dynamics of N6-methyladenosine (m6A) in STEMI and the Impact of IL-6 Inhibition  
**Camilla Huse** (Norway)
- No. 04** Elevated adipose inflammation, but reduced hepatic triacylglycerol storage in diet-induced obese Plin4-null mice.  
**Atanaska Doncheva** (Norway)

**YIA Poster walk I**  
**10.00 – 10.45**

**Selected abstracts (3 min presentation + 2 min discussion)**

- No. 05** Location-dependent proteomics of the aortic arch from apolipoprotein E deficient mice  
**Kathrine V. Jokumsen** (Denmark) - YIA
- No. 06** Uncovering the role of liver lymphatic vessels in MASLD using hyperlipidemic mouse models with disturbed lymphatic development  
**Krista Hokkanen** (Finland) - YIA
- No. 07** The Role of Gasdermins in Atherosclerotic Plaque Destabilization: Gasdermin D and E – A Murder Mystery  
**Michelle Zurek** (Finland) - YIA
- No. 08** Insights into the role of NPC2 in vascular inflammation and atherosclerosis  
**Jakob Hansen** (Denmark) - YIA
- No. 09** Heterogenous phenotypic modulation of smooth muscle cells by mechanical stretch and TNF stimulation.  
**Lise Filt Jensen** (Denmark) - YIA

**SESSION II**

**CARDIOVASCULAR DISEASE**

- No. 10** Efficacy and safety of short-term S100A8/A9 blockade in a myocardial ischemia-reperfusion injury porcine model  
**Minja Heikkilä** (Finland)

- No. 11** A dual MAGL/HSL inhibitor showing therapeutic efficacy in dyslipidemic APOE\*3-Leiden.CETP mice  
**Jingxi Zhu** (Netherlands)
- No 12** Regulation of Endothelial Lipase by Angiopoietin-like Protein 3  
**Marina Mutas** (Denmark)
- No 13** Comprehensive lipid and metabolite profiling of long-term survivors of type 1 diabetes compared to healthy controls: cross-sectional results from the Dialong study in Norway  
**Jacob J. Christensen** (Norway)
- YIA Poster walk II** **Selected abstracts (3 min presentation + 2 min discussion)**  
**19.30 – 20.30**
- No. 14** Characterization of isocitrate dehydrogenase (IDH)-associated macrophage responses in atherosclerosis  
**Michelle Due Nilsson** (Denmark) - YIA
- No. 15** Taurine-conjugated fatty acid metabolites reduce atherosclerosis in LDLR<sup>-/-</sup> mice  
**Katja Thorøe Michler** (Denmark) - YIA
- No. 16** Association of aerobic fitness and body composition with protein and major lipid class composition of high-density lipoprotein  
**Emilia Lähteenmäki** (Finland) - YIA
- No. 17** Impaired anti-inflammatory capacity of high-density lipoprotein is associated with high residual cardiovascular risk in coronary artery disease  
**Wanying Wu** (China) - YIA
- No. 18** SGLT-i Modify Exosomal Protein Composition: A potential Mechanism for Cardioprotective Effects  
**Jana Dudová** (Czech Republic) - YIA

Friday, April 4, 2025

Posters are displayed in "Lille Sal". Posters should be mounted before 9.00 and removed after the last poster session of the day. You should be present at your poster during both poster sessions of the day. Your poster should be mounted on the board with your number on.

**SESSION III**

**LIPOPROTEINS AND LIPID TRANSPORT**

- No. 19** Circulating ApoC-III glycoforms identifies patients with metabolic dysfunction-associated steatotic liver disease independently of type 2 diabetes.  
**Gabriele Mocciaro** (UK)
- No. 20** Combining comprehensive cardiometabolic risk biomarker panels with machine learning to predict survival in severe COVID-19 patients admitted to the intensive care unit.  
**Debra Dorotea** (Sweden)
- No. 21** Reduced lipid synthesis and oxidation but upregulated mitochondrial responses in cultured myotubes established from AMPK $\alpha$ 2<sup>-/-</sup> mice  
**Arild C. Rustan** (Norway)
- No. 22** Deciphering Atherosclerosis in Type 2 Diabetes: A Novel Exploration of Biomarkers in Interstitial Fluid  
**Cecilia Morgantini** (Sweden)
- No. 23** Trafficking of LDL-derived cholesterol by combined live-cell imaging and lipid mass spectrometry of novel fluorescent cholesteryl esters  
**Daniel Wüstner** (Denmark)

**YIA Poster walk III**  
**10.00 – 11.00**

**Selected abstracts (3 min presentation + 2 min discussion)**

- No. 24** MARC1 downregulation reduces hepatocyte lipid content by increasing beta-oxidation.  
**Tanmoy Dutta** (sweden) - YIA
- No. 25** PXR agonist rifampicin elevates serum Lp(a) levels substantially.  
**Topias Kotilainen** (Finland) - YIA
- No. 26** Functional Impact of APOB Variants in Familial Hypercholesterolemia  
**Maria Ferreira** (Portugal) - YIA
- No. 27** Elucidating the degradation pattern of apolipoprotein B-100 from human carotid atherosclerotic plaques by N-terminal proteomics.  
**Nicoline Wichmand Thorsen** (Denmark) - YIA
- No. 28** The effect of SGLT2 inhibitors on human apoM levels in proximal tubular cells under LPS-induced cell damage.  
**Daniele Angelo Renato Villa** (Denmark) - YIA

- No. 29** The impact of sex hormones and sex chromosomes on the HDL anti-inflammatory activity  
**Ana Vankova** (Sweden) - YIA
- No 30** VLDL triglycerides and cholesterol in non-alcoholic fatty liver disease and myocardial infarction  
**Lærke Kristine Kyhl** (Denmark) - YIA
- No 31** Lipoprotein(a) Testing Among General Practitioners in Norway: Shaping the Future of Cardiovascular Risk Stratification  
**Janeni Jeevanathan** (Norway) - YIA
- SESSION IV** **OTHER TOPICS**
- No. 32** Dietary restriction of sulfur amino acid in humans has impact on serum free fatty acids and apelin gene expression in adipose tissue: findings from an 8-week randomized controlled trial.  
**Emma Stolt** (Norway)
- No. 33** Competitive displacement of lipoprotein lipase from heparan sulfate is orchestrated by a disordered acidic cluster in GPIHBP1  
**Anamika Biswas** (Denmark)
- No. 34** Supplementation of seaweed extracts to the diet reduces symptoms of Alzheimer's Disease in the APP<sup>swe</sup>PS1 $\Delta$ E9 mouse model  
**Monique Mulder** (Netherlands)
- No. 35** Levels of selected aminothiols in a group of patients with arterial hypertension and/or atherosclerosis after COVID-19  
**Beata Sarecka-Hujar** (Poland)
- No. 36** Comprehensive lipid and metabolite profiling of youth with childhood onset type 1 diabetes compared to healthy controls: Results from the Norwegian ACD study  
**Jacob J Christensen** (Norway)
- No 37** Analysis of arterial stiffness parameters assessed by photoplethysmography in patients with arterial hypertension and/or atherosclerosis according to gender  
**Danuta Łoboda** (Poland)
- No 38** Dietary effects on metabolic health and ageing in liver  
**Marit Hjorth** (Norway)
- YIA Poster walk IV** **Selected abstracts (3 min presentation + 2 min discussion)**  
**14.45 – 15.45**
- No. 39** Mapping uptake and dissolution of ingested cholesterol crystals in macrophages using combined fluorescence and x-ray microscopy.  
**Vibeke Akkerman** (Denmark) - YIA

- No. 40** Familial Hypercholesterolemia (FH): 25 years of findings in the Portuguese FH Study  
**Beatriz Miranda** (Portugal) - YIA
- No. 41** Effect of cetoleic acid-enriched fish oil on atherosclerosis markers in high-risk patients with metabolic syndrome  
**Iselin Schjelle Holen** (Norway) - YIA
- No. 42** Orthopedic events and incident amyloidosis in the general population  
**Søren Nicolaj Rønborg** (Denmark) - YIA
- No. 43** The Regulation and Effect of m6A Modification on the atherosclerotic plaque and Vascular Smooth Muscle Cells (VSMCs)  
**Hamida Anwari** (Norway) - YIA